UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript

May 10, 2022 4:35 PM ETUroGen Pharma Ltd. (URGN)
SA Transcripts profile picture
SA Transcripts

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET

Company Participants

Vincent Perrone - Senior Director of IR

Liz Barrett - President and CEO

Mark Schoenberg - Chief Medical Officer

Jeff Bova - Chief Commercial Officer

Don Kim - CFO

Conference Call Participants

Ram Selvaraju - H.C. Wainwright

Boris Peaker - Cowen

Chris Howerton - Jefferies

Matt Kaplan - Ladenburg Thalmann

Leland Gershell - Oppenheimer

Anita Dushyanth - Berenberg Capital


Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's First Quarter 2022 Financial Results and Business Update Conference Call.

It is now my pleasure to turn the call over to Vincent Perrone, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.

Vincent Perrone

Thank you, operator. Good morning everyone and welcome to UroGen Pharma's first quarter 2022 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31, 2021. The press release can be accessed on the Investors portion of our website at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities relating to Jelmyto ongoing and planned clinical trials, commercial and clinical milestones in the year ahead. The potential of UGN-102 to transform the treatment paradigm as the first viable nonsurgical alternative for low-grade intermediate risk NMIBC, potential future commercialization activities for UGN-102, if approved, data presentations, regulatory filings, future research and development efforts, our goals, potentially reaching cash flow breakeven by 2025 and 2022 financial guidance, among other things.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.